Trial intelligence / Profile preview

Inclisiran in Heterozygous Familial Hypercholesterolemia (ORION-9)

NCT03397121Phase 3Completed

Sponsor
The Medicines Company
Start
Nov 2017
Primary completion
Aug 2019
Modality
Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
Countries
8
01

Overview

A Phase 3 trial of inclisiran in heterozygous familial hypercholesterolemia (HeFH), sponsored by The Medicines Company. Started Nov 2017; status: completed.

02

Drugs

inclisiran
03

Conditions

heterozygous familial hypercholesterolemia (HeFH)

Beyond the preview

Go deeper on NCT03397121.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT03397121.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call